Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02144077 | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy | completed | Phase 3 | 281 | Biofrontera Bioscience GmbHINDUSTRY | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02066636 | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen(CheckMate153) | completed | Phase 3 | 1,428 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 27, 2022 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT00866918 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia | completed | Phase 3 | 106 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT00482833 | Phase III Trial in Acute Promyelocytic Leukemia Patients(APL0406) | completed | Phase 3 | 276 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 3 | Oct 12, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT03465722 | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | completed | Phase 3 | 476 | Blueprint Medicines CorporationINDUSTRY | 18 | Oct 6, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT03066778 | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Oct 3, 2022 | clinicaltrials |
| NCT01335399 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma(ELOQUENT - 1) | completed | Phase 3 | 748 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 30, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT02412878 | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma(ARROW) | completed | Phase 3 | 478 | AmgenINDUSTRY | 20 | Sep 23, 2022 | clinicaltrials |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | Phase 3 | 792 | AmgenINDUSTRY | 20 | Sep 21, 2022 | clinicaltrials |
| NCT01968941 | Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients(LUSTRE) | completed | Phase 3 | 324 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02747043 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab(JASMINE) | completed | Phase 3 | 256 | AmgenINDUSTRY | 20 | Sep 10, 2022 | clinicaltrials |
| NCT03922997 | A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 101 | Hoffmann-La RocheINDUSTRY | 1 | Sep 9, 2022 | clinicaltrials |
| NCT02843386 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma(FOTEADJ) | completed | Phase 3 | 302 | Institut CurieOTHER | 2 | Aug 31, 2022 | clinicaltrials |
| NCT00549848 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | completed | Phase 3 | 600 | St. Jude Children's Research HospitalOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
| NCT00199108 | Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt | completed | Phase 2 / Phase 3 | 20 | Goethe UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT01535053 | Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia | completed | Phase 3 | 57 | GOG FoundationNETWORK | 5 | Aug 12, 2022 | clinicaltrials |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | completed | Phase 3 | 821 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 9, 2022 | clinicaltrials |
| NCT04342377 | The Canada Lymph Node Score Project: A Crossover Trial(CLNS) | completed | Phase 3 | 80 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00347412 | Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | completed | Phase 3 | 903 | Cellectar Biosciences, Inc.INDUSTRY | 12 | Jul 25, 2022 | clinicaltrials |
| NCT02425891 | A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | completed | Phase 3 | 902 | Hoffmann-La RocheINDUSTRY | 40 | Jul 19, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT01721772 | Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma(CheckMate 066) | completed | Phase 3 | 418 | Bristol-Myers SquibbINDUSTRY | 16 | Jul 12, 2022 | clinicaltrials |
| NCT02330471 | Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial(CONE-1) | completed | Phase 3 | 160 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02714218 | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | completed | Phase 3 | 387 | Bristol-Myers SquibbINDUSTRY | 13 | Jun 24, 2022 | clinicaltrials |
| NCT01303796 | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(SEAMLESS) | completed | Phase 3 | 482 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 12 | Jun 22, 2022 | clinicaltrials |
| NCT02063685 | Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma | completed | Phase 3 | 807 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT00913705 | Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer(NATCH) | completed | Phase 3 | 624 | Spanish Lung Cancer GroupOTHER | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | completed | Phase 3 | 305 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT01239797 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma(ELOQUENT - 2) | completed | Phase 3 | 646 | Bristol-Myers SquibbINDUSTRY | 23 | Jun 1, 2022 | clinicaltrials |
| NCT00006455 | Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)(ALCL 99) | completed | Phase 3 | 885 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 10 | May 31, 2022 | clinicaltrials |
| NCT03029234 | Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | completed | Phase 3 | 126 | AmgenINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT01117441 | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia | completed | Phase 3 | 6,136 | University Hospital Schleswig-HolsteinOTHER | 7 | May 24, 2022 | clinicaltrials |
| NCT02197221 | Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma(IFM2014-02) | completed | Phase 3 | 300 | University Hospital, ToulouseOTHER | 2 | May 23, 2022 | clinicaltrials |
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)(GENUINE) | completed | Phase 3 | 126 | TG Therapeutics, Inc.INDUSTRY | 2 | May 20, 2022 | clinicaltrials |
| NCT02383966 | Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer(CHANGE2) | completed | Phase 3 | 243 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)(ENLIVEN) | completed | Phase 3 | 120 | Daiichi SankyoINDUSTRY | 12 | May 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 3, 2022source: clinicaltrials